Pathway Genomics and Salud Interactiva announce partnership to bring advanced clinical genetic testing to millions in Mexico

SAN DIEGO, CA —-Pathway Genomics and Salud Interactiva, a company backed by Sinca Inbursa, today announced a partnership that will make Pathway’s wide range of clinical genetic testing with advanced Artificial Intelligence analysis available to millions of Salud Interactiva’s users in Mexico. Salud Interactiva, a leading third party administrator offering health services in 3 countries, has a network of over 6 million users and associations comprised of insurance companies, private clinics (e.g. Bio Clinique), and other corporate partners.

Pathway Genomics to Present at the 2017 UBS Global Healthcare Conference

SAN DIEGO–(BUSINESS WIRE)–Pathway Genomics, an innovative commercial-stage genomics company, announced today that Dr. Michael Nova, Chief Innovation Officer, and Kamal Adawi, Chief Financial Officer, will present at the 2017 UBS Global Healthcare Conference. This event will be held at the Grand Hyatt in New York City on Monday, May 22nd through May 24th. Pathway’s presentation will take place Monday, May 22, 2017 at 3:00 p.m. EDT. The presentation will be available on Pathway.com.

Pathway Genomics to participate in NASDAQ Fit Week

San Diego, CA – (BUSINESS WIRE) – January 2, 2017 — Pathway Genomics, an innovative commercial-stage genomics company, announced today that they will be participating in the 7th annual NASDAQ Fit Week. PathwayFit®, their test that assesses 80 genetic markers to help personalize and optimize diet, nutrition, metabolic health and exercise regimes, will be featured at Fit Week. As part of the event, Pathway will be offering PathwayFit® for a special price of $199 during the month of January and will also kick off the “This Is My Pathway” video contest to help create awareness about making informed, proactive lifestyle decisions.

Pathway Genomics to Present & Exhibit at The 24th Annual World Congress on Anti-Aging Medicine

San Diego, CA – (BUSINESS WIRE) – December 8, 2016 —Pathway Genomics, an innovative commercial-stage genomics company, announced today that Dr. Michael Nova, Chief Innovation Officer, will present at the 24th Annual World Congress on Anti-Aging Medicine in Las Vegas, Nevada. Dr. Nova will present on Nutritional Genetics and Epigenetics in Diabetes and Obesity Management on Friday December 9th at 2:55pm in the Veronese Room (2503-4/2403-4) at the Venetian Hotel. Additionally, Pathway will be exhibiting at the conference in booth 3098.

Pathway Genomics’ Chief Financial Officer, Kamal Adawi, to present at the 28th Annual Piper Jaffray Healthcare Conference

San Diego, CA – (BUSINESS WIRE) – November 28, 2016 — Pathway Genomics, an innovative commercial-stage genomics company, announced today that Kamal Adawi, Chief Financial Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference. This conference will be held at The Lotte New York Palace in New York City on November 29th and 30th and the presentation will be made available on Pathway.com and Pathway’s social media.

“Pathway is honored to be a part of this important conference,” said Jim Plante, Founder & CEO. “We believe that proactively sharing healthcare industry knowledge helps us all gain a broader perspective that ultimately allows us to help more patients.”

G-TAC – M3 (a Sony Company) and Pathway Genomics Partner to Market CancerIntercept™, BRCATrue® and Fitness Genetic Tests in Japan

TOKYO — (BUSINESS WIRE) — G-TAC Co., Ltd. and M3, Inc. (an associated company of SONY) announced a strategic business partnership with Pathway Genomics to market fourteen tests including CancerIntercept™, BRCATrue®, PathwayFit®, SkinFit™ and other genetic tests through G-TAC’s genomics network of over 20,000 physicians in Japan.

Pathway Genomics Provides Updates for CancerIntercept™ Detect Clinical Program

SAN DIEGO May 26, 2016  – Pathway Genomics today provided an update on the clinical development program for its liquid biopsy, CancerIntercept™ Detect, a non-invasive screening test for detection of mutations that have been associated with cancer. Pathway Genomics researchers have initiated a clinical trial for the detection of thyroid cancer – the company’s third ongoing study for the technology. The company also announced the publication of two abstracts in the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings.

“The initiation of the thyroid study is an important step in our clinical development program for CancerIntercept and will help increase our understanding of its potential as a biomarker for the early detection of thyroid cancer,” said Glenn Braunstein, M.D., chief medical officer of Pathway Genomics. “We are in the process of initiating additional disease specific studies for early cancer detection in high risk patients, including a study in lung cancer, and will present and publish the data in the appropriate forums.”